Colorectal Pulmonary Metastases: Pulmonary Metastasectomy Versus Stereotactic Ablative Radiotherapy

Launched by AMSTERDAM UMC, LOCATION VUMC · Apr 10, 2023

Keywords

ClinConnect Summary

The COPPER trial is a clinical study designed to compare two different treatments for patients with up to three lung tumors caused by colorectal cancer. The two treatment options being studied are surgical removal of the tumors (called metastasectomy) and a special type of radiation therapy known as Stereotactic Ablative Radiotherapy (SABR). This trial will help doctors understand which method is more effective for treating these specific lung metastases.

To participate in the trial, you must be at least 18 years old, have a good performance status (meaning you can carry out daily activities), and have been treated for colorectal cancer in the past. You should have one to three lung tumors that can be treated with either of the two methods being studied. Participants will be asked to complete quality-of-life questionnaires to help researchers learn more about how these treatments impact daily living. It's important to know that the trial is not currently recruiting participants, so if you're interested, you will need to wait until it begins.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age ≥ 18 years
• • Eastern Cooperative Oncology Group (ECOG)-Performance status 0 - 2
• • Willing to provide informed consent
• • Patients with 1 to 3 lung metastases from colorectal cancer eligible for both a minimally invasive surgical resection and SABR, as assessed by the multidisciplinary tumor board (MDT)
• • Radically treated primary colorectal cancer
• • Patient is able and willing to complete the quality-of-life questionnaires
• • Previous liver metastases are radically treated with curative intent
• • Histologically confirmed malignancy with metastatic disease detected on imaging. Biopsy of metastasis is preferred, but not required.
• Exclusion Criteria:
• • Previous or present metastases outside liver or lungs
• • Concurrent malignant cancer, or history of other malignant cancers within the past 5 years (excluding prespecified low-risk cancers)
• • Hilar or mediastinal lymph node metastases
• • Poor cardiopulmonary function test
• • Inability to treat all colorectal metastases
• • Surgical resection by means of a bilobectomy or pneumonectomy